Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection

Lok, A.S.; Wilson, L.A.; Thomas, H.C.

Journal of Antimicrobial ChemoTherapy 14(1): 93-99

1984


ISSN/ISBN: 0305-7453
PMID: 6207158
DOI: 10.1093/jac/14.1.93
Accession: 043736062

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Thirty-one patients with chronic HBV infection were randomized to receive a short or long course of ARA-AMP. Fifteen completed a 4 week course of treatment and 16 completed longer courses varying from 7 to 12 weeks. Eighteen patients did not experience any neurological side effects. Six patients had myalgia. This was not associated with any neurological deficit. Seven patients developed a sensory neuropathy with distressing pain and dysesthesiae in the feet and abnormalities in nerve conduction. The development of neurotoxicity was related to a long duration of treatment and a correspondingly higher total dose but there was no association with the severity of liver disease.